ghk cu copper peptides injection peptide pen GHK-Cu Peptide GHK-CU - Research Peptide -

It rarely presents with skin rash, but is most notable for hypersensitivity reactions upon infusion

In 2010, the FDA approved Egrifta for the treatment of excess visceral fat (belly fat) in HIV patients with lipodystrophy 2

The FDA's 2023 PCAC briefing document cited insufficient clinical evidence to support therapeutic compounding approval

You dont have to struggle through every day feeling like youre running on fumes

Further, NICE and the BNF says that if there are neurological symptoms present, then every other day injections are the recommended treatment, so all the points you make about B12 being stored and sufficient are not really relevant